SecBot SecBot

AGEN

AGENUS INC
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001098972 Biotech & Drug Discovery
$6.29 −0.44 (−6.54%)
Nov 16 4:00 PM ET · prev $6.73
Market cap
$310.8M
Small cap
Consensus
Buy
89% Buy or better · 9 analysts
Median target
$25.00
+297% · range $16.00–40.00
1 year
+45.6%
from $4.32 · Nov 17
30 days
+1.8%
from $6.18
52-week range
$2.77–9.93
−37% from high · low Feb 5
Avg volume 20D
683.3K
shares / day
Short interest
7.60M
≈16.8% of shares · +8.5%
Days to cover
10.7
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
1
Q3 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 2/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 22 added (1 new), 10 trimmed or exited.

  • AnalystsBULLISH

    8 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.040 → −$0.220 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +8.5% to 7.60M shares. 10.7 days to cover, ≈16.8% of shares.

  • TrendDOWNTREND

    14% below its 50-day average.

Who's buying

13F· Q3 2026
1
new positions
0
exits
FundMoveSharesValue
MARSHALL WACE, LLPADD786,350$7.8M
STATE STREET CORPADD756,378$7.5M
MORGAN STANLEYADD381,104$3.8M
UBS Group AGDOUBLED207,677$2.1M
Connor, Clark & Lunn Investment Management Ltd.TRIM158,447$1.6M
PANAGORA ASSET MANAGEMENT INCTRIM99,246$985.5K
RHUMBLINE ADVISERSADD50,631$502.8K
STRS OHIOTRIM46,500$461.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 89% rate it Buy or better
Strong Buy2Buy6Hold1Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +297%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 9, 2026B. Riley Securities
REITERATE
REITERATEBuy
Oct 26, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 22, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 5, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Sep 28, 2026Rodman & Renshaw
INITIATE
INITIATEBuy
Sep 18, 2026Chardan Capital
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 1, 2026
Wright Timothy
Director
Oct 1, 2026
AWARD1,178.764 sh
Oct 1, 2026
HARRISON THOMAS L
Director
Oct 1, 2026
AWARD$30.6K
Aug 10, 2026
ARMEN GARO H
See Remarks
Aug 10, 2026
AWARD1,971,500 sh
Aug 5, 2026
Marcucci Marco Tullio
Director
Aug 5, 2026
AWARD7,500 sh
Aug 5, 2026
Hirsch Susan B
Director
Aug 5, 2026
AWARD50,000 sh
Aug 5, 2026
Buell Jennifer
See Remarks
Aug 5, 2026
AWARD200,000 sh
Aug 5, 2026
O'Day Steven J
Chief Medical Officer
Aug 5, 2026
AWARD100,000 sh
Aug 5, 2026
Wright Timothy
Director
Aug 5, 2026
AWARD50,000 sh

Earnings setup

Estimates
−$0.22
EPS estimate, this quarter
−650%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.22-$0.22–-$0.22-650.0%$30.9M
Next Q-$0.15-$0.15–-$0.15No data$23.2M
Current FY$0.82$0.82–$0.82No data$130.7M
Next FY-$0.16-$0.16–-$0.16-45.5%$123.2M

Short side

FINRA· Oct 30, 2026
7,596,037
shares short
+8.5%
vs prior settlement
10.7
days to cover
≈16.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 13, 2026 SEC
Eventide Asset Management disclosed a 5.4% passive stake in Agenus Inc via Schedule 13G, representing 2,446,789 shares…
SC 13G · Impact 3/10
Nov 6, 2026 Earnings result
AGEN Q3 2026 Earnings: EPS $0.02 (+107.3% vs est)
Nov 5, 2026 SEC
Agenus reported Q3 2026 total revenue of $31.5M (up 4% YoY from $30.2M) and net income of $2.8M, its third consecutive…
8-K · Impact 4/10
Oct 1, 2026 Insider
Wright Timothy was granted 1,178.764 shares
Director
Oct 1, 2026 Insider
HARRISON THOMAS L was granted 4,443 shares
Director @ $6.89 ($30.6K)
Sep 30, 2026 Inst.
MARSHALL WACE, LLP · ADD
786,350 shares ($7.8M)
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
756,378 shares ($7.5M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

12 filings · 1 bullish · 4 bearish · 1 mixed · 6 neutral
All AGEN filing & press-release reports (12)